Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis

Video

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

Vaishali Sanchorawala, MD, director of Stem Cell Transplantation program at Boston Medical Center, director of Amyloidosis Center at Boston University School of Medicine, and secretary of the International Society of Amyloidosis for the term 2020-2022, discusses the impact of renal and cardiac response on survival in patients with light chain (AL) amyloidosis. 

Research from 2 international collaborative studies presented during the 2021 International Myeloma Workshop 2021 examined the graded renal response criteria and revised renal progression criteria for AL amyloidosis, as well as the graded cardiac response criteria and the impact of depth of cardiac response on survival, according to Sanchorawala. 

Results showed that a deeper cardiac response was associated with improved overall survival (OS), Sanchorawala says. Additionally, deeper renal response correlated with improved OS, as well as renal survival which translated to a decreased risk for renal replacement therapy, Sanchorawala concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD